Ozempic and Wegovy linked to rare risk of sudden vision loss
In brief
A study led by Rutgers researchers found a modest association between GLP-1 medications, including Ozempic and Wegovy, and a rare condition that can cause sudden vision loss. The study does not show that the drugs directly cause the condition, but researchers say the small increase in risk merits awareness and continued safety monitoring as use grows.
Study finds modest association
GLP-1 drugs include semaglutide, marketed as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. Researchers found use of the medications was associated with a slightly higher likelihood of ischemic optic neuropathy.
Understanding the eye condition
Ischemic optic neuropathy occurs when reduced blood flow damages the optic nerve, which carries visual information from the eye to the brain. More than 80% of cases are estimated to involve the non-arteritic anterior form, affecting the nerve’s front portion.
Vision loss is often permanent, though Dave said about one-third of affected patients experience some recovery, usually within six months. The condition commonly affects part of the vision in one eye; symptoms can include sudden blurriness, dimming or missing areas.
Risk remains low
The condition was uncommon in the study. Dave said the increase amounted to about three to four additional cases per 10,000 patients treated with GLP-1s over 18 months.
Cases occurred more often among men and adults in the older part of the study population, including those ages 50 to 65. The medications are prescribed to people with and without Type 2 diabetes, making ongoing safety monitoring important, researchers said.
Cause remains uncertain
The findings do not establish that GLP-1 medications directly damage the optic nerve. Differences in patients’ underlying health conditions or other factors may help account for the observed association, and further research is needed.
Dave said prompt eye evaluation may be important for people at higher baseline risk who experience sudden vision loss. Researchers emphasized recognizing new vision changes and seeking medical assessment.
Key points
- GLP-1 use was associated with a small increase in a rare optic nerve condition.
- The estimated increase was three to four additional cases per 10,000 patients over 18 months.
- The study does not prove the medications cause optic nerve damage.
- Sudden blurriness, dimming or missing areas of vision warrant prompt medical evaluation.